Cargando…
A New Modality in Dyslipidemia Treatment: Antisense Oligonucleotide Therapy
There are unmet needs for pharmacologic agents beyond current medications, such as statins, to effectively lower low-density lipoprotein cholesterol levels to target goals, especially in patients with very high or extremely high risk. Pharmacological targeting of mRNA represents an emerging, innovat...
Autores principales: | Kim, Kyuho, Choi, Sung Hee |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society of Lipidology and Atherosclerosis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515732/ https://www.ncbi.nlm.nih.gov/pubmed/36212748 http://dx.doi.org/10.12997/jla.2022.11.3.250 |
Ejemplares similares
-
Antisense Oligonucleotides and Small Interfering RNA for the Treatment of Dyslipidemias
por: Gareri, Clarice, et al.
Publicado: (2022) -
New treatments for myasthenia: a focus on antisense oligonucleotides
por: Angelini, Corrado, et al.
Publicado: (2013) -
Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease
por: Sardone, Valentina, et al.
Publicado: (2017) -
Antisense Oligonucleotide-Based Therapy of Viral Infections
por: Tarn, Woan-Yuh, et al.
Publicado: (2021) -
Development of Antisense Drugs for Dyslipidemia
por: Yamamoto, Tsuyoshi, et al.
Publicado: (2016)